Clinical Trial Update: Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy [Phase 2]

View source ↗

Summary

Phase 2 study assessing intermittent dosing of imatinib in patients with chronic myeloid leukemia who achieved complete cytogenetic response on standard imatini…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Università degli Studi di Brescia | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED